Electrospinning of bioresorbable polymers is a promising and valuable scaffolding technique. To improve its potential applications, the addition of specific fillers has been considered. This paper reports the fabrication of electrospun poly(L-lactic acid)/Ca-deficient-hydroxyapatite (PLLA/dHAp) mats, the content of nanosized d-HAp ranged between 1 and 8 wt%. All samples consisted of micrometric and submicrometric fibers, comprising 2D voids of 8 and 13 µm for PLLA and PLLA/d-HAp mats, respectively. The surface of the electrospun fibers was characterized by an uniform distribution of nanopores. Hybrid mats loaded with 1 wt% d-HAp showed the most homogeneous microstructure, differently from the mats loaded with 4 and 8 wt% d-HAp due to the presence of microagglomerates. The viscoelastic properties of PLLA/d-HAp hybrids were characterized by a decreasing trend of the storage modulus with increases in the nanofiller content. The microstructure, viscoelastic behavior, and cytocompatibility were investigated using murine bone marrow mesenchymal stem cells. On the basis of the biological data, the electrospun PLLA and PLLA/d-HAp mats can be regarded as potential scaffolds for bone marrow mesenchymal stem cells culture.

Tissue engineering represents a potential and valuable approach for the treatment of urologic pathologies. Bioresorbable polymeric scaffolds can be regarded as effective platforms to surgically treat bladder diseases and subsequently guide the formation of novel tissue after implantation. To this aim, the evaluation of electrospun scaffolds made up of poly(ε-caprolactone) blended with poly(3-hydroxybutyrate-co-3-hydroxyvalerate) is presented here. Firstly, the microstructure and the viscoelastic/mechanical properties of the electrospun fabrics were investigated. Then, the in vivo response was assessed by performing a urinary bladder augmentation using female Wistar rats as an animal model. 15 days after the surgical procedure, the scaffolds were covered by regenerative urothelium up to 50%, which increased to 50–100% after 30 days. These encouraging results, collected in the 90-day follow-up, clearly showed the potential applications of tissue engineering in the urologic field. A longer in vivo evaluation is currently underway.